Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints.
作者信息
Hasan Fariha, Hasan Bilal
机构信息
Dow University of Health Sciences, 11/1, Phase 6 Main Khayaban e Sehar Dha, Karachi, 74200, Pakistan.
Aga Khan University, Karachi, Pakistan.
出版信息
Ther Adv Endocrinol Metab. 2017 Dec;8(12):173-174. doi: 10.1177/2042018817737955. Epub 2017 Nov 7.
Abstract
摘要
相似文献
1
Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints.抗糖尿病药物与死亡率降低：从替代终点到临床终点的转变。
Ther Adv Endocrinol Metab. 2017 Dec;8(12):173-174. doi: 10.1177/2042018817737955. Epub 2017 Nov 7.
2
[Surrogate end point fallacies -- the urge for randomized trials with clinical endpoints].[替代终点的谬误——开展具有临床终点的随机试验的迫切需求]
Psychother Psychosom Med Psychol. 2006 May;56(5):193-201. doi: 10.1055/s-2005-915449. Epub 2006 Mar 3.
3
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.心血管疾病风险降低的替代终点和新兴替代终点。
Nutr Rev. 2008 Feb;66(2):76-81. doi: 10.1111/j.1753-4887.2007.00010.x.
4
The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.临床试验中替代终点的应用：聚焦于心血管疾病的临床试验。
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):497-508. doi: 10.1002/pds.654.
5
Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.当代心血管临床试验中替代终点的使用趋势
Am J Cardiol. 2016 Jun 1;117(11):1845-50. doi: 10.1016/j.amjcard.2016.03.021. Epub 2016 Mar 19.
6
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.九项新降糖药物心血管结局大型临床试验的网状荟萃分析。
Prim Care Diabetes. 2019 Jun;13(3):204-211. doi: 10.1016/j.pcd.2019.01.003. Epub 2019 Jan 31.
7
[Surrogate endpoints in clinical studies exemplified by HIV infection].[以HIV感染为例的临床研究中的替代终点]
Schweiz Med Wochenschr. 1998 Jul 7;128(27-28):1079-88.
8
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂、胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂的成本效益：系统评价。
Pharmacoeconomics. 2019 Jun;37(6):777-818. doi: 10.1007/s40273-019-00774-9.
9
Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan.在患有糖尿病的患者中使用多种抗糖尿病药物及其与低血糖事件的关系：在约旦的病例交叉研究。
BMJ Open. 2018 Nov 21;8(11):e024909. doi: 10.1136/bmjopen-2018-024909.
10
Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.抗糖尿病药物作为抗高血压药物：新的前景数据。
Curr Vasc Pharmacol. 2017;16(1):70-78. doi: 10.2174/1570161115666171010122332.
引用本文的文献
1
Association between prescription drugs and all-cause mortality risk in the UK population.英国人群中处方药与全因死亡风险之间的关联。
Aging Cell. 2024 Dec;23(12):e14334. doi: 10.1111/acel.14334. Epub 2024 Oct 4.
本文引用的文献
1
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.用于治疗2型糖尿病的非胰岛素药物的心血管益处及安全性。
Postgrad Med. 2017 Nov;129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27.
2
Early Glycemic Control and Magnitude of HbA Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators.早期血糖控制和 HbA1c 降低幅度可预测心血管事件和死亡：24752 名二甲双胍使用者的基于人群的队列研究。
Diabetes Care. 2017 Jun;40(6):800-807. doi: 10.2337/dc16-2271. Epub 2017 Apr 12.
3
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.1 型和 2 型糖尿病的死亡率和心血管疾病。
N Engl J Med. 2017 Apr 13;376(15):1407-1418. doi: 10.1056/NEJMoa1608664.
4
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.抗糖尿病药物对2型糖尿病大血管并发症发生率和死亡率的影响：钠-葡萄糖协同转运蛋白2抑制剂的新视角
Ann Med. 2017 Feb;49(1):51-62. doi: 10.1080/07853890.2016.1226514. Epub 2016 Sep 22.
5
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?2 型糖尿病的血糖控制与血管结局：情况清晰吗？
Diabetes Care. 2016 Aug;39 Suppl 2:S187-95. doi: 10.2337/dcS15-3023.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.恩格列净心血管结局研究（EMPA-REG）及其他降糖药物心血管结局试验：对2型糖尿病未来治疗策略的启示
Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.
8
Effects of intensive glucose lowering in type 2 diabetes.强化降糖对2型糖尿病的影响。
N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.
9
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.2型糖尿病患者强化血糖控制与血管转归
N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.
Zotero 插件